Abstracts

COMPLETED GENOME-INTACT UNSPLICED HIV TRANSCRIPTS ARE RARE IN EX VIVO CD4+ CELLS

During virologic rebound, HIV-infected cells must produce 5′ to 3′ completed, genome-intact and unspliced (CGIU) viral transcripts for packaging into new virions. Conventional methods to study HIV transcription are unable to obtain genome-intactness information. Here, we present a novel high-fidelity long-read sequencing method, TranSeq, and profiled HIV transcriptomes in clinically-derived CD4+ cells with emphasis on…

PROFILING THE PROVIRAL LANDSCAPE IN TISSUES FROM ART-TREATED INDIVIDUALS

HIV reservoir cells that circulate in blood have been well characterized, but little is known about the dissemination of HIV-1-infected cells across multiple anatomical tissues, especially the central nervous system (CNS). Here, we performed single-genome near-full-length proviral sequencing to evaluate the proviral landscape in multiple tissues from 2 ART-treated patients. Frozen tissues derived from 2…

LONGITUDINAL DYNAMICS OF INTACT PROVIRAL HIV-1 DNA IN POSTTREATMENT CONTROLLERS

In HIV-1 infected individuals, discontinuation of antiretroviral combination therapy (cART) typically results in rapid viral rebound. However, a small number of individuals, termed post-treatment controllers (PTCs), exhibit sustained virologic suppression for months or years following cART interruption. The dynamics and evolution of the proviral reservoirs of these individuals are largely unknown. Samples from 3 PTCs,…

CELL-FREE DNA PREDICTS HIV REBOUND TIMING FOLLOWING ANTIRETROVIRAL THERAPY CESSATION

The development of HIV cure strategies depends on our capacity to predict HIV rebound when antiretroviral therapy (ART) is stopped. Here, we applied a systems profiling approach to the analytical treatment interruption (ATI) framework, to identify circulating plasma factors that enable non-invasive prediction of viral rebound kinetics post-ART cessation. Plasma samples were retrospectively collected from…

IMMUNE MARKERS AND TO TIME TO REBOUND DURING HIV TREATMENT INTERRUPTION IN ACTG A5345

Understanding factors that affect viral rebound timing during antiretroviral treatment interruption will accelerate efforts toward inducing sustained HIV remission. We evaluated whether immunologic parameters prior to treatment interruption are predictive of time to rebound in individuals interrupting ART in a highly monitored setting. A5345 enrolled individuals who started ART in chronic or early infection and…